Thibault Gauduchon, T. Reverdy, A. Karabajakian, L. Collet, Max Gau, E. Neidhardt, J. Fayette
{"title":"HNSCC和免疫治疗:一个漫长故事的开始","authors":"Thibault Gauduchon, T. Reverdy, A. Karabajakian, L. Collet, Max Gau, E. Neidhardt, J. Fayette","doi":"10.4172/2155-9929.1000412","DOIUrl":null,"url":null,"abstract":"The immunotherapy revolution has not spared Head and neck squamous cell carcinoma (HNSCC). Checkpoint inhibitors (anti-PD-1 / PD-L1) were the first to be validated in second line treatment and soon come to the first line in local or metastatic recurrence. Many studies are currently underway to expand the indications of these new therapies, whether as monotherapy or in combination. In addition, immunotherapy is not limited to checkpoint inhibitors and many other immunotherapy molecules are currently under study. The selection of patients who benefit from immunotherapy and the evaluation of the response to these treatments are problems not completely solved. The aim here is to present the state of art on immunotherapy in HNSCC.","PeriodicalId":89808,"journal":{"name":"Journal of molecular biomarkers & diagnosis","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2155-9929.1000412","citationCount":"0","resultStr":"{\"title\":\"HNSCC and Immunotherapy: The Beginning of a Long Story\",\"authors\":\"Thibault Gauduchon, T. Reverdy, A. Karabajakian, L. Collet, Max Gau, E. Neidhardt, J. Fayette\",\"doi\":\"10.4172/2155-9929.1000412\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The immunotherapy revolution has not spared Head and neck squamous cell carcinoma (HNSCC). Checkpoint inhibitors (anti-PD-1 / PD-L1) were the first to be validated in second line treatment and soon come to the first line in local or metastatic recurrence. Many studies are currently underway to expand the indications of these new therapies, whether as monotherapy or in combination. In addition, immunotherapy is not limited to checkpoint inhibitors and many other immunotherapy molecules are currently under study. The selection of patients who benefit from immunotherapy and the evaluation of the response to these treatments are problems not completely solved. The aim here is to present the state of art on immunotherapy in HNSCC.\",\"PeriodicalId\":89808,\"journal\":{\"name\":\"Journal of molecular biomarkers & diagnosis\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4172/2155-9929.1000412\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of molecular biomarkers & diagnosis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-9929.1000412\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of molecular biomarkers & diagnosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-9929.1000412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
HNSCC and Immunotherapy: The Beginning of a Long Story
The immunotherapy revolution has not spared Head and neck squamous cell carcinoma (HNSCC). Checkpoint inhibitors (anti-PD-1 / PD-L1) were the first to be validated in second line treatment and soon come to the first line in local or metastatic recurrence. Many studies are currently underway to expand the indications of these new therapies, whether as monotherapy or in combination. In addition, immunotherapy is not limited to checkpoint inhibitors and many other immunotherapy molecules are currently under study. The selection of patients who benefit from immunotherapy and the evaluation of the response to these treatments are problems not completely solved. The aim here is to present the state of art on immunotherapy in HNSCC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
